The Veterans Research and Education Foundation of St. Louis is administering a new clinical trial, the ROXI-EVEREST study, to evaluate a new potential treatment for stroke and systemic embolism prevention.
About the Study
ROXI-EVEREST is a phase 3, randomized, multicenter, double-blind study. Its purpose is to assess the prevention of stroke and systemic embolism using REGN7508, a monoclonal antibody against factor XI, compared to apixaban.
Participant Eligibility
This study is designed for participants with atrial fibrillation (AF) who are at risk for stroke and/or systemic embolism and for whom oral anticoagulation is unsuitable.
If you are interested in learning more, please discuss with your healthcare provider to determine if this trial may be right for you.
Principal Investigator
Dr. Nathan Stitziel
Principal InvestigatorFor more information about the EVEREST study, please contact the research team.
Sponsorship and Administration
This study is administered by the Veterans Research and Education Foundation of St. Louis (VREF) and funded by Regeneron Pharmaceuticals Inc.